Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Nature Chemical Biology|October 11, 2016
SF2312 is a natural phosphonate inhibitor of enolasePaul G Leonard, Nikunj Satani, David Maxwell, et al.Cancer Cell|April 4, 2020
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung CancerHunain Alam, Ming Tang, Mayinuer Maitituoheti, et al.Journal of Medicinal Chemistry|October 17, 2022
Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of <i>ENO1</i>-Deleted CancersVictoria C Yan, Cong-Dat Pham, Elliot S Ballato, et al.Biorxiv : the Preprint Server for Biology|May 22, 2023
Anaplerotic nutrient stress drives synergy of angiogenesis inhibitors with therapeutics targeting tumor metabolismSunada Khadka, Yu-Hsi Lin, Jeffrey Ackroyd, et al.Nature Communications|July 10, 2021
Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosineYasaman Barekatain, Jeffrey J Ackroyd, Victoria C Yan, et al.Nature Medicine|August 15, 2018
Author Correction: Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancerYonathan Lissanu Deribe, Yuting Sun, Christopher Terranova, et al.Nature Medicine|June 13, 2018
Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancerYonathan Lissanu Deribe, Yuting Sun, Christopher Terranova, et al.Nature Metabolism|November 24, 2020
An enolase inhibitor for the targeted treatment of ENO1-deleted cancersYu-Hsi Lin, Nikunj Satani, Naima Hammoudi, et al.Cell Reports|October 21, 2020
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant MelanomaMayinuer Maitituoheti, Emily Z Keung, Ming Tang, et al.Cancer Cell|July 12, 2017
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the MicroenvironmentQianghu Wang, Baoli Hu, Xin Hu, et al.Pageof 3